- Home
- EWTX vs SRRK Comparison
EWTX vs SRRK Comparison
Compare EWTX & SRRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EWTX
- SRRK
- Stock Information
- Founded
- EWTX 2017
- SRRK 2012
- Country
- EWTX United States
- SRRK United States
- Employees
- EWTX N/A
- SRRK N/A
- Industry
- EWTX Biotechnology: Pharmaceutical Preparations
- SRRK Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- EWTX Health Care
- SRRK Health Care
- Exchange
- EWTX Nasdaq
- SRRK Nasdaq
- Market Cap
- EWTX 3.3B
- SRRK 2.8B
- IPO Year
- EWTX 2021
- SRRK 2018
- Fundamental
- Price
- EWTX $31.98
- SRRK $26.67
- Analyst Decision
- EWTX Strong Buy
- SRRK Strong Buy
- Analyst Count
- EWTX 5
- SRRK 7
- Target Price
- EWTX $40.40
- SRRK $34.00
- AVG Volume (30 Days)
- EWTX 679.5K
- SRRK 881.4K
- Earning Date
- EWTX 11-07-2024
- SRRK 11-12-2024
- Dividend Yield
- EWTX N/A
- SRRK N/A
- EPS Growth
- EWTX N/A
- SRRK N/A
- EPS
- EWTX N/A
- SRRK N/A
- Revenue
- EWTX N/A
- SRRK N/A
- Revenue This Year
- EWTX N/A
- SRRK N/A
- Revenue Next Year
- EWTX N/A
- SRRK N/A
- P/E Ratio
- EWTX N/A
- SRRK N/A
- Revenue Growth
- EWTX N/A
- SRRK N/A
- 52 Week Low
- EWTX $5.93
- SRRK $6.76
- 52 Week High
- EWTX $38.12
- SRRK $35.38
- Technical
- Relative Strength Index (RSI)
- EWTX 46.84
- SRRK 50.69
- Support Level
- EWTX $29.82
- SRRK $25.75
- Resistance Level
- EWTX $38.12
- SRRK $28.30
- Average True Range (ATR)
- EWTX 1.93
- SRRK 1.66
- MACD
- EWTX -0.70
- SRRK -0.67
- Stochastic Oscillator
- EWTX 26.02
- SRRK 17.64
About EWTX Edgewise Therapeutics Inc.
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of innovative treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases.
About SRRK Scholar Rock Holding Corporation
Scholar Rock Holding Corp is a biopharmaceutical company. It is engaged in the discovery and development of innovative medicines for the treatment of serious diseases including neuromuscular disorders, cancer, fibrosis, and anemia. Geographically, the company operates in the United States. The company's product candidate is Apitegroma which is a selective, fully human, monoclonal antibody, with a mechanism of action that results in inhibition of the activation of the growth factor, myostatin, in skeletal muscle. Its other product comprises SRK-181, an inhibitor of the activation of latent transforming growth factor beta-1 ("TGFβ1"), for the treatment of cancers that are resistant to anti-PD-(L)1 antibody therapies.